Browse
We’re here to help

Find guidance on Author Services

Login | Register

Login
Register

Cart Add to Cart

Search
Browse
We’re here to help

Find guidance on Author Services

Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 27, Issue 3

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

About this journalAbout

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Register a free Taylor & Francis Online account today to boost your research and gain these benefits:

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Register now or learn more

Expert Opinion on Investigational Drugs, Volume 27, Issue 3 (2018)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 27, Issue 3 (2018)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Volume 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Inhaled medication therapy for bronchiectasis: status quo and the next frontier

Chun-lan Chen, Yan Huang, Yong-hua Gao, Rong-chang Chen, Nan-shan Zhong & Wei-jie Guan

Pages: 211-218

Published online: 15 Feb 2018

First Page PreviewforInhaled medication therapy for bronchiectasis: status quo and the next frontier | Full Text | References | PDF (730.7 KB)

2370 Views
2 CrossRef citations
0Altmetric

Free Access

Editorial

Drug development and acute gastrointestinal infections

Hania Szajewska, Maciej Kołodziej & Jan Łukasik

Pages: 219-224

Published online: 26 Dec 2017

First Page PreviewforDrug development and acute gastrointestinal infections | Full Text | References | PDF (590.4 KB)

1392 Views
0 CrossRef citations
0Altmetric

Free Access

Review

Investigational drug therapies for coeliac disease – where to from here?

James Haridy, Diana Lewis & Evan D. Newnham

Pages: 225-233

Published online: 20 Feb 2018

AbstractforInvestigational drug therapies for coeliac disease – where to from here? | Full Text | References | PDF (722.2 KB)

355 Views
0 CrossRef citations
0Altmetric

Review

Investigational opioid antagonists for treating opioid-induced bowel dysfunction

Shilan Mozaffari, Shekoufeh Nikfar & Mohammad Abdollahi

Pages: 235-242

Published online: 26 Dec 2017

AbstractforInvestigational opioid antagonists for treating opioid-induced bowel dysfunction | Full Text | References | PDF (744.6 KB)

207 Views
4 CrossRef citations
0Altmetric

Review

NS5B polymerase inhibitors in phase II clinical trials for HCV infection

Guglielmo Borgia, Alberto Enrico Maraolo, Salvatore Nappa, Ivan Gentile & Antonio Riccardo Buonomo

Pages: 243-250

Published online: 28 Dec 2017

AbstractforNS5B polymerase inhibitors in phase II clinical trials for HCV infection | Full Text | References | PDF (642.3 KB)

229 Views
0 CrossRef citations
0Altmetric

Review

Advancements in drug development for diarrhea-predominant irritable bowel syndrome

Giovanni Dothel, Maria Raffaella Barbaro, Emanuel Raschi, Giovanni Barbara & Fabrizio De Ponti

Pages: 251-263

Published online: 22 Feb 2018

AbstractforAdvancements in drug development for diarrhea-predominant irritable bowel syndrome | Full Text | References | PDF (1.1 MB)

281 Views
0 CrossRef citations
0Altmetric

Review

Investigational drugs in development to prevent neuromyelitis optica relapses

Friedemann Paul, Olwen Murphy, Santiago Pardo & Michael Levy

Pages: 265-271

Published online: 28 Feb 2018

AbstractforInvestigational drugs in development to prevent neuromyelitis optica relapses | Full Text | References | PDF (579.4 KB)

800 Views
2 CrossRef citations
0Altmetric

Review

Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis

Alberto Gajofatto & Marco Turatti

Pages: 273-286

Published online: 23 Feb 2018

AbstractforInvestigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis | Full Text | References | PDF (1 MB)

325 Views
0 CrossRef citations
0Altmetric

Drug Evaluation

Article

Inclisiran for the treatment of dyslipidemia

Toshiyuki Nishikido & Kausik K. Ray

Pages: 287-294

Published online: 22 Feb 2018

AbstractforInclisiran for the treatment of dyslipidemia | Full Text | References | PDF (804.9 KB)

1929 Views
5 CrossRef citations
0Altmetric

Article

Filgotinib for the treatment of Crohn’s disease

Remi Labetoulle, Stephane Paul & Xavier Roblin

Pages: 295-300

Published online: 28 Feb 2018

AbstractforFilgotinib for the treatment of Crohn’s disease | Full Text | References | PDF (538 KB)

995 Views
2 CrossRef citations
0Altmetric

Article

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

Frank Tacke

Pages: 301-311

Published online: 22 Feb 2018

AbstractforCenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis | Full Text | References | PDF (1.2 MB)

1779 Views
4 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Early psoriatic arthritis: clinical and therapeutic challenges.

Francesco Caso et al.

Review Article | Published online: 23 Jul 2024

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

Elisabeth Amadeo et al.

Review Article | Published online: 22 Jul 2024

Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

Robert H. Gaffey et al.

Review Article | Published online: 17 Jul 2024

Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects

Jian Liu et al.

Article | Published online: 12 Jul 2024

Open Access

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.27, Iss.3, 2018)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?